Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTA Centessa Pharmaceuticals plc

Closed Good Friday 04-17 16:00:00 EDT

12.30

+0.47

+3.93%

盘后12.30

+0.000.00%

16:09 EDT

High12.30	Low11.87	Vol784.65K
Open11.87	D1 Closing11.83	Amplitude3.63%
Mkt Cap1.64B	Tradable Cap1.14B	Total Shares133.18M
T/O9.52M	T/O Rate0.84%	Tradable Shares93.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CNTA","market":"US","secType":"STK","nameCN":"Centessa Pharmaceuticals plc","latestPrice":12.295,"timestamp":1744920000000,"preClose":11.83,"halted":0,"volume":784645,"hourTrading":{"tag":"盘后","latestPrice":12.295,"preClose":12.295,"latestTime":"16:09 EDT","volume":2330,"amount":28648.56,"timestamp":1744920552618},"delay":0,"floatShares":93006186,"shares":133184349,"eps":-2.05949,"marketStatus":"Closed Good Friday","change":0.465,"latestTime":"04-17 16:00:00 EDT","open":11.87,"high":12.3,"low":11.87,"amount":9520594.477032,"amplitude":0.036348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.05949,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1622174400000,"exchange":"NASDAQ","adjPreClose":11.83,"preHourTrading":{"tag":"盘前","latestPrice":11.9,"preClose":11.83,"latestTime":"08:40 EDT","volume":261,"amount":3044.550123,"timestamp":1744893611021},"postHourTrading":{"tag":"盘后","latestPrice":12.295,"preClose":12.295,"latestTime":"16:09 EDT","volume":2330,"amount":28648.56,"timestamp":1744920552618},"volumeRatio":0.9544800206893514,"impliedVol":0.8302,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/CNTA","defaultTab":"news","newsList":[{"id":"2523489869","title":"Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2523489869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523489869?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:34","pubTimestamp":1743420858,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals (CNTA) has an average rating of buy and mean price target of $31.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CNTA"],"gpt_icon":0},{"id":"2523919159","title":"Centessa Pharmaceuticals Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2523919159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523919159?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:16","pubTimestamp":1743416160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 06:16 ET (10:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA"],"gpt_icon":0},{"id":"2523291587","title":"Centessa initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2523291587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523291587?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 17:36","pubTimestamp":1743413764,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin initiated coverage of Centessa (CNTA) with an Overweight rating and $38 price target The company is developing a m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/centessa-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/centessa-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4535","BK4139","CNTA"],"gpt_icon":0},{"id":"2522802936","title":"Centessa Pharmaceuticals Price Target Maintained With a $28.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802936?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:57","pubTimestamp":1742997420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:57 ET (13:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA"],"gpt_icon":0},{"id":"2522703043","title":"Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2522703043","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522703043?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 01:51","pubTimestamp":1742838660,"startTime":"0","endTime":"0","summary":"1351 ET - As Centessa Pharmaceuticals reports results and predicts a \"data-rich\" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. \"Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year,\" the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 \"appear to be lower than competitors at same stage of development.\" TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA"],"gpt_icon":0},{"id":"2521746972","title":"Centessa Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Misses $(0.40) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746972","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746972?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:06","pubTimestamp":1742814386,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Misses $(0.40) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44454658/centessa-pharmaceuticals-q4-2024-gaap-eps-0-84-misses-0-40-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA"],"gpt_icon":0},{"id":"2521745072","title":"Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745072?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024. -- Advancing a broad, potential best-in-class orexin receptor 2 . agonist franchise with key data readouts expected in 2025. -- ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy. type 1 , narcolepsy type 2  and idiopathic hypersomnia.  well underway and on track with data expected across all. three indications in 2025 with first-in-class potential in NT2 and. Dr. Saha concluded, \"In addition to the transformational potential of ORX750 for individuals living with sleep-wake disorders, we see tremendous opportunity with our follow-up OX2R agonists that are being advanced for the treatment of EDS, impaired attention, cognitive deficits and fatigue in neurological, neurodegenerative and neuropsychiatric disorders. ORX142 is prog","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","BK4139","MSL","ESS","NSS","BK4218","BK4588","BK4178","BK4539","BK4585","BK4215","BK4597","BK4510","BK4232","AAN","BK4085","BK4535","PK","BK4181","BK4563","IH","CNTA"],"gpt_icon":0},{"id":"2519488753","title":"Does Centessa Pharmaceuticals (NASDAQ:CNTA) Have A Healthy Balance Sheet?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519488753","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519488753?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 20:04","pubTimestamp":1742040267,"startTime":"0","endTime":"0","summary":"Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnta/centessa-pharmaceuticals/news/does-centessa-pharmaceuticals-nasdaqcnta-have-a-healthy-bala","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","QLD","NVIW.SI","LU2095319765.USD","BK4539","MNQmain","USJW.SI","CNTA","IE00B3QW5Z07.USD","NQmain","BK4588","TQQQ","BK4112","EBIT","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","TSYW.SI","NDAQ","BK4139","QID","IE00BKPKM429.USD","IE00BGHQF748.EUR","USAW.SI","PSQ","BK4535",".IXIC"],"gpt_icon":1},{"id":"2519702568","title":"Centessa Pharmaceuticals Plc : Leerink Partners Raises Target Price to $36 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2519702568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519702568?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:35","pubTimestamp":1741952106,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nFWN3PX10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4539","BK4139","CNTA"],"gpt_icon":0},{"id":"2517550554","title":"Centessa Pharmaceuticals Coverage Assumed by Morgan Stanley at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2517550554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517550554?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 01:24","pubTimestamp":1741368240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 12:24 ET (17:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA"],"gpt_icon":0},{"id":"2517191113","title":"Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191113?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:14","pubTimestamp":1741295640,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, March 06, 2025  -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 , narcolepsy type 2  and idiopathic hypersomnia , will be presented in a poster sessionat the American Academy of Neurology  2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial  in participants with NT1, NT2 and IH.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centessa-pharmaceuticals-announces-poster-presentation-211400184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","CNTA","AFG","BK4107","AAN","IH","BK4117","BK4510","BK4535","BK4085","BK4178","BK4563"],"gpt_icon":1},{"id":"2517911246","title":"TD Cowen Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911246?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:19","pubTimestamp":1741180792,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Stacy Ku maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report) today. The company’s shares closed yesterday...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","CNTA","COWN"],"gpt_icon":0},{"id":"2513726635","title":"TD Cowen Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726635?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:06","pubTimestamp":1740402407,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Stacy Ku maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report) today. The company’s shares closed last Frid...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","CNTA","TD"],"gpt_icon":0},{"id":"2505768774","title":"Analysts Conflicted on These Healthcare Names: Ironwood Pharma (IRWD) and Centessa Pharmaceuticals (CNTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505768774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505768774?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 11:50","pubTimestamp":1737517855,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD – Research Report) and Cente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ironwood-pharma-irwd-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ironwood-pharma-irwd-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTA","BK4535","BK4539","BK4137","HCSG","BK4139","IRWD"],"gpt_icon":0},{"id":"2503589612","title":"Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589612","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589612?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 22:51","pubTimestamp":1736779875,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Centessa Pharmaceuticals plc  stands against the other best medical stocks under $20.The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now and 8 Undervalued Insurance Stocks To Invest In.According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence  is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.However,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-centessa-pharmaceuticals-cnta-among-145115603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDC","TSYW.SI","BK4510","QID","NQmain","BK4208","IH","LU1894683348.USD","MNQmain","NVIW.SI","BK4563","PSQ","QQQ","BK4539","BK4535",".IXIC","CMS","SQQQ","BK4588","TQQQ","LU1894683264.USD","CNTA","BK4085","LU2637428348.USD","BK4139","LU2346227817.USD","USAW.SI","BK4585","QLD","USJW.SI"],"gpt_icon":0},{"id":"2503446340","title":"Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Celldex (CLDX) and Centessa Pharmaceuticals (CNTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503446340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503446340?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 14:14","pubTimestamp":1736748852,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avidity Biosciences (RNA – Research Report), Celldex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avidity-biosciences-rna-celldex-cldx-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avidity-biosciences-rna-celldex-cldx-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4539","RNA","BK4588","CLDX","BK4505","HCSG","BK4585","CNTA","BK4535"],"gpt_icon":0},{"id":"2502078165","title":"Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502078165","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502078165?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 06:14","pubTimestamp":1736460863,"startTime":"0","endTime":"0","summary":"12 Best Growth Stocks Under $25 to Buy Now.In this article, we are going to take a look at where Centessa Pharmaceuticals plc  stands against the other growth stocks.AI is the Most Defining Theme of 2025, Says Expert. Most experts agree that the AI wave is not over yet. On January 8, Wendy Sheehan Donnell, Editor-in-Chief at PCMag, joined Yahoo Finance from CES 2025 to share her take on trending innovations and the increasing role of artificial intelligence in revolutionizing industries.Donnell unveiled some of the groundbreaking innovations spearheaded by companies from across the globe and emphasized that \"AI is the prevailing theme\" across all these new products and services. She highlighted the incidence of AI-powered home devices such as smart microwaves and fridgesto help people live smarter and tech-immersed lives. She also shed light on the growing role of AI in healthcare and biotechnology, which will contribute to the well-being of people.Why are we interested in the stocks t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centessa-pharmaceuticals-plc-cnta-best-221423766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","USJW.SI","TSYW.SI","CNTA","PSQ","MNQmain","TQQQ","NQmain","USAW.SI","SQQQ","BK4535",".IXIC","QID","NVIW.SI","BK4139","QLD"],"gpt_icon":1},{"id":"2502010100","title":"Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Centessa Pharmaceuticals (CNTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502010100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502010100?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 22:10","pubTimestamp":1736431806,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Senseonics Holdings (SENS – Research Report) and C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-senseonics-holdings-sens-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-senseonics-holdings-sens-and-centessa-pharmaceuticals-cnta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","CNTA","HCSG","SENS","BK4137","BK4139","BK4539","BK4082"],"gpt_icon":0},{"id":"2501723047","title":"Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501723047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501723047?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 20:05","pubTimestamp":1736337900,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, Jan. 08, 2025  -- Centessa Pharmaceuticals plc , a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer . Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.\"Orexin agonists are one of the most exciting emerging areas of therapeutic science, and Centessa's potential best-in-class OX2R agonists represent an extraordinary opportunity to address unmet patient needs across multiple therapeutic areas,\" said Stephen Kanes, MD PhD, Chief Medical Officer. \"With Phase 2a clinical studies of ORX750 now underway, it's an exciting time to be joining Centessa. I look forward to working with the team and contributing to the success of the Company's growing OX2R agonist franchise.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","01698","BK4510","LU0359202008.SGD","BK4022","IE00BYTNYN87.SGD","SG9999011746.SGD","LU0359201612.USD","IH","IE00BYQNZ168.SGD","BK4561","IE00B12V2V27.USD","BK4196","BK4563","LU1023057109.AUD","BK4539","BK4535","BK4548","LU2039709279.SGD","BK4552","BK4571","BK4526","CNTA","BK4085","CMO","BK4108","BK4121","BK4139","MD","BK4530","BK4565","PPD","BK4531","TME","BK4509"],"gpt_icon":0},{"id":"2501089205","title":"TD Cowen Initiates Centessa Pharmaceuticals ADR at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2501089205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501089205?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 21:01","pubTimestamp":1736254886,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals ADR (CNTA) has an average rating of buy and mean price target of $28.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","CNTA","BK4566","COWN","BK4207","TD","BK4139","BK4539","BK4127","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.centessa.com","stockEarnings":[{"period":"1week","weight":0.0909},{"period":"1month","weight":-0.2553},{"period":"3month","weight":-0.189},{"period":"6month","weight":-0.234},{"period":"1year","weight":0.1405},{"period":"ytd","weight":-0.266}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.043931},{"month":2,"riseRate":0.25,"avgChangeRate":0.004574},{"month":3,"riseRate":0.75,"avgChangeRate":0.02482},{"month":4,"riseRate":0.25,"avgChangeRate":-0.034068},{"month":5,"riseRate":0,"avgChangeRate":-0.195432},{"month":6,"riseRate":1,"avgChangeRate":0.130556},{"month":7,"riseRate":0.5,"avgChangeRate":0.064685},{"month":8,"riseRate":0.75,"avgChangeRate":0.077935},{"month":9,"riseRate":0.25,"avgChangeRate":-0.068989},{"month":10,"riseRate":0.5,"avgChangeRate":-0.006613},{"month":11,"riseRate":0.5,"avgChangeRate":-0.049856},{"month":12,"riseRate":0.25,"avgChangeRate":-0.003223}],"exchange":"NASDAQ","name":"Centessa Pharmaceuticals plc","nameEN":"Centessa Pharmaceuticals plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Centessa Pharmaceuticals plc(CNTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Centessa Pharmaceuticals plc,CNTA,Centessa Pharmaceuticals plc股票,Centessa Pharmaceuticals plc股票老虎,Centessa Pharmaceuticals plc股票老虎国际,Centessa Pharmaceuticals plc行情,Centessa Pharmaceuticals plc股票行情,Centessa Pharmaceuticals plc股价,Centessa Pharmaceuticals plc股市,Centessa Pharmaceuticals plc股票价格,Centessa Pharmaceuticals plc股票交易,Centessa Pharmaceuticals plc股票购买,Centessa Pharmaceuticals plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Centessa Pharmaceuticals plc(CNTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction